FDA Refusal to Review Moderna mRNA Flu Vaccine Signals Shift in U.S. Policy

In a move that has sent shockwaves through the biotechnology industry, the U.S. Food and Drug Administration (FDA) has officially declined to review Moderna’s application for its new mRNA-based influenza vaccine. The decision, delivered via an unusual "refusal-to-file" letter, marks a significant escalation in the Trump administration's tightening of vaccine regulations.

Dr. Vinay Prasad, director of the Center for Biologics Evaluation and Research (CBER), cited concerns over Moderna’s clinical trial design as the sole reason for the rejection. The agency argued that the trial was not "adequate and well-controlled" because Moderna compared its experimental shot to standard, existing flu vaccines rather than the "best-available standard of care," such as high-dose shots for high-risk individuals.

Moderna has vehemently disputed this reasoning. CEO Stéphane Bancel stated that the agency had previously discussed and agreed upon the trial design before the studies began. Company officials highlighted that the FDA’s letter did not identify any specific safety or efficacy concerns. In fact, the new vaccine—designed to be updated more quickly than traditional egg-based shots—elicited better antibody responses than existing vaccines in clinical tests.

The rejection follows a series of policy shifts under Health and Human Services Secretary Robert F. Kennedy Jr., a prominent critic of mRNA technology. The administration has recently moved to limit routine childhood vaccine recommendations and has canceled millions in research funding for mRNA projects.

Legal and medical experts warn that this decision creates a climate of "decisional volatility" that could discourage future investment in life-saving technologies. While Moderna’s application remains under review in Europe, Canada, and Australia, its future in the U.S. market remains uncertain as the company seeks a meeting with regulators to "understand the path forward".

---

🔖 Sources

F.D.A. Refuses to Review Moderna Flu Vaccine

Moderna says FDA refuses to review its application for experimental flu shot

FDA declines to review Moderna application for new flu vaccine

---

Keywords: FDA Refusal to Review Moderna mRNA Flu Vaccine

FDA Refusal to Review Moderna mRNA Flu Vaccine

---